Form 8-K - Current report:
SEC Accession No. 0001759425-24-000005
Filing Date
2024-02-28
Accepted
2024-02-28 16:05:28
Documents
15
Period of Report
2024-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mirm-20240228.htm   iXBRL 8-K 27567
2 EX-99.1 mirm-20240228xexx991.htm EX-99.1 121216
  Complete submission text file 0001759425-24-000005.txt   287700

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mirm-20240228.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mirm-20240228_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mirm-20240228_pre.xml EX-101.PRE 12508
16 EXTRACTED XBRL INSTANCE DOCUMENT mirm-20240228_htm.xml XML 2848
Mailing Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404
Business Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 650-667-4085
Mirum Pharmaceuticals, Inc. (Filer) CIK: 0001759425 (see all company filings)

EIN.: 831281555 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38981 | Film No.: 24695204
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)